STRICTLY CONFIDENTIAL AND NOT FOR DISTRIBUTION



# THE KEY INGREDIENTS OF A SUCCESSFUL M&A DEAL

ADAM S. PARKER, Ph.D., FOUNDER

adam@trivariateresearch.com 646-734-7070

CHANG GE, ANALYST

chang@trivariateresearch.com 614-397-0038

MAXWELL ARNOLD, ANALYST

maxwell@trivariateresearch.com 347-514-1234

RYAN MCGOVERN, DIR. OF RESEARCH SALES

ryan@trivariateresearch.com 973-271-8017

COLIN COONEY, HEAD OF SALES

colin@trivariateresearch.com 617-910-7934

## **OUTLINE AND CONCLUSIONS**

Today's research on M&A is broken into three sections:

- 1) Summary statistics: Data on the M&A landscape, including by style, substance, size, transaction size, type of deal (public / private, non-US vs. US), and transaction type (cash, stock, combination). See Slide 3 for key summary points.
- 2) Post-announcement results: How did the acquirers trade right after the deal announcement and what acquirer and deal attributes were associated with strong or poor results. See Slide 9 for key summary points.
- 3) 3-Year Results: How did the acquirers trade for the three-years after the deal announcement and what acquirer and deal attributes were associated with strong or poor results. See Slide 15 for key summary points.

#### **CONCLUSIONS:**

On average over the last 25-years, acquirers have performed poorly, with GROWTH companies performing the worst, lagging their industry-averages by 12% over the subsequent three years. Acquirers engaging in all stock deals perform worse than those that do all cash deals. Performance of acquirers that buy non-US public companies is inferior to those buying US targets. Private deals are better than public deals. Expensive companies shouldn't do deals. Avoiding targets with low net margins and those that don't have extremely high forecasted revenue growth will increase the chance of success. Acquirers that are cheap, not growth, and using all cash to buy a private company appear to have the most attributes of a successful acquisition. Recent deal announcements and the key attributes are shown on Slide 20.

## SUMMARY DESCRIPTIVE STATISTICS OF M&A THE LAST 25 YEARS

Background: The conventional wisdom is that 2025 will be a big year for Mergers & Acquisitions (M&A). Less regulation and pent-up demand have most of the lawyers and investment bankers we know quite busy these last few weeks. Hence, we looked at all M&A for the last 25 years for US companies, small-cap or larger, that did a deal of at least 10% of the market capitalization, where they acquired more than 50% of the target. Our study is comprised of 2,948 announced deals. The median transaction size of the M&A we evaluated was about 25% of the market cap. of the acquirer, across the market cap. spectrum. Of the announced deals we studied 91% ultimately closed.

Size, style, substance: Among the acquirers we analyzed, 56% were small-caps, 29% mid-caps, and 15% mega-/large-caps. About one-third of the acquirers were growth stocks, one-third value, and one-third in the middle ground we call neither. The acquirers were also evenly distributed across substance quartile, with between 20% and 30% in each of high-, and mid-, low-, and junk quality.

Public / private, domestic / foreign: 56% of all the transactions we analyzed were a US public company buying another public company, and 44% were a US public company buying a private company. Among the US companies that bought public companies, 80% of the targets were US, and 20% were foreign public equities.


**Sector**: Financials and Real Estate are the sectors that have engaged in the highest number of deals in the last 25 years, followed by Technology and Healthcare. Communication Services and Utilities have the fewest number of deals.


Transaction type and size: 45% of deals were cash only, 31% were offered through a combination of stock and cash, and 24% were stock only. Interestingly, the median stock deal appeared to be much larger (46% of the acquirer's market cap.) vs. the median all cash stock deal (21% of the acquirer's market cap).



## WE ANALYZED NEARLY 3000 DEALS, 58% WERE SMALL CAPS


We looked at all M&A for the last 25 years for US companies, small-cap or larger, that did a deal of at least 10% of their market capitalization, where they acquired more than 50% of the target. Our study comprises of 2,948 announced deals. There have recently been three relatively light years of M&A, and many including us think 2025 is poised to see an increase in activity (left). Among the acquirers we analyzed, 56% were small-caps, 29% mid-caps, and 15% mega-/large-caps (right).






#### ACQUIRERS WERE EVENLY DISTRIBUTED BY STYLE AND SUBSTANCE


Among the deals we analyzed, about one-third of the acquirers were growth stocks, one-third value, and one-third in the middle ground we call neither (left). The acquirers were also evenly distributed across substance quartile, with between 20% and 30% in high-, mid-, low-, and junk quality (right).






## NEARLY ½ OF DEALS ARE PRIVATE, 80% OF THE PUBLICS ARE US

Of the deals we analyzed, 56% were a US public company buying another public company, and 44% were a US public company buying a private company (left). Among the US companies that bought public companies, 80% of the targets were US, and 20% were foreign public equities (right).







Source: Trivariate Research

## FINS / REITS HAVE THE MOST ACTIVITY, 45% OF DEALS ARE ALL CASH


Financials and Real Estate are the sectors that have engaged in the highest number of deals in the last 25 years (left), followed by Technology and Healthcare. Communication Services and Utilities have the fewest number of deals. 45% of deals were cash only, 31% were offered through a combination of stock and cash, and 24% were stock only (right).






## THE MEDIAN TRANSACTION IS 25% OF THE ACQUIRER

The median transaction size of the M&A we evaluated was about 25% of the market capitalization of the acquirer (left), independent of the acquirer's size. On the right, we show that the median stock deal appeared to be much larger (46% of the acquirer's market cap.) vs. the median all cash deal (21% of the acquirer's market cap).





Source: Trivariate Research

## POST-ANNOUNCEMENT RESULTS

Background: We studied the returns of the acquirers for a full-trading day post the deal announcement relative to their industry group average. Note: the "deal reaction" is a 1- or 2-day stock return around the given date. If the date happens on a non-trading day, then this is the 1-day return from the previous close to the next close (ex: Friday close to Monday close if date occurs on weekend). If the date happens on a trading day, then this is the 2-day stock return from the close on the trading day before the date to the close on the next trading date after the given date.

Substance and size: Over the past 25 years, high-quality companies that do acquisitions have the worst initial reaction, where as junk stocks buying something tend to perform better. Only small-caps have a positive average initial reaction to deal announcements, with mega-/large-cap. acquirers averaging more than 1% post-announcement retreat on the first day.

**Transaction type:** Companies doing all stock deals have a much worse initial reaction to the announcement, down nearly 1.5% vs. their industries' performance on average, vs. acquisitions done in all cash, which on average perform well. Public companies buying private companies have better performance immediately following an announcement vs. when they buy another public company.


Acquirer's valuation and beta matter: The stocks that are in the cheapest quintile of price-to-forward earnings and announce deals perform more than  $\frac{1}{2}$  percent better than acquirers in the most expensive 40%. Acquirers that are high beta also tend to lag.

The target's growth and margins don't matter: There is little Day 1 performance differential for acquirers buying targets with high forecasted growth vs. low growth, or high vs. low net margin.

**Sector performance**: The only sector with a positive relative-to-industry performance for the first full trading day following a deal announcement is Consumer Discretionary. On average, Technology acquirers have the worst first day reaction.


## LARGE-CAP/HIGH-QUALITY ACQUIRERS HAVE WORST DAY 1 REACTION

We studied the returns of the acquirers for a full-trading day post the deal announcement relative to their industry group averages. Over the past 25 years, high-quality companies that do acquisitions have the worst initial reaction, whereas junk stocks buying something tend to perform better (left). Only small-caps have a positive average initial reaction to deal announcements, with mega-/large-cap. acquirers averaging more than 1% post-announcement retreat on the first day (right).



## USING ALL STOCK TO BUY A PUBLIC COMPANY MEANS A POOR 1ST DAY


Companies doing all stock deals have a much worse initial reaction to the announcement, down nearly 1.5% vs. their industries' performance on average, vs. acquisitions done in all cash, which on average perform well (left). Importantly, we mentioned in the summary statistics section, the average stock deal is typically larger, which likely conflates the results. Public companies buying private companies (right) have better performance immediately following an announcement (beating their industry average by 1%) vs. when they buy another public company (lagging by 1%).






## CHEAP DEALMAKERS DO BEST, HIGH BETA DO POORLY ON AVERAGE

The acquirer's valuation matters for the initial performance following a deal announcement (left). The stocks that are in the cheapest quintile of price-to-forward earnings and announce deals perform more than ½ percent better than the acquirers in the most expensive 40%. Acquirers that are high beta also tend to lag, though beta doesn't seem to matter unless it is in the highest 20%.



## DISCRETIONARY ACQUIRERS ARE POSITIVE DAY 1 PERFORMERS


The only sector with a positive relative-to-industry performance for the first full trading day following a deal announcement is Consumer Discretionary. On average, Technology acquirers have the worst first day reaction. Financial, Real Estate, and Healthcare also average a poor Day 1 performance. Materials stocks perform relatively inline following an acquisition announcement.






#### REVENUE GROWTH AND MARGINS DON'T SEEM TO INITIALLY MATTER

We broke the forecasted revenue growth of the targets into quintiles to investigate whether forecasted growth was associated with the initial market reaction of the acquirer. The answer is, not really, or maybe on the margin targets with higher growth cause a slightly *worse* reaction (left). This likely is because investors think they overpaid for the growth. The net margins don't seem to matter much, meaning acquirers buying high margin companies are treated in the following day's performance about the same as acquirers buying low margin businesses.





#### THREE-YEAR RESULTS

In aggregate, doing a deal isn't a good idea: The average acquirer lags its industry group by 6% over the subsequent three years following a deal. Clearly, performance of growth companies doing deals is much worse than value, or the middle ground, neither. In fact, the average growth company that does an acquisition lags its industry-group's performance by 12% over the next three years.

The transaction type matters: The average acquirer doing an all-stock deal lags its industry group average by 11% over the next three years. Buying a foreign company on average results in inferior performance versus buying a US company, likely from less-than-expected cost synergies.


Expensive companies shouldn't do deals: Companies that are in the most expensive quintile of EV-to-forecasted sales and do a deal on average lag their industry groups by 10% over the next three years. Valuation doesn't seem to be a differentiator for the acquirer unless the company is in the most expensive quintile. The target's valuation does seem to matter more. Acquisitions of targets in the cheapest quintile perform in-line with their industries over the next three years, whereas those in the most expensive quintile lag by 10% on average.


Low net margins and forecasted growth of targets are negatives for acquirer: We analyzed the profitability and forecasted revenue growth of the companies receiving the tender offer to see if that had an impact on the subsequent stock performance of the acquirer. Performance of acquirers buying companies in the lowest net margin quintile was on average poor, lagging the acquirer's industry-average by 12% over the next three years. Avoiding very fast growers was also prudent, though this is highly correlated to price.

Slide 20 shows the most recent deals and their key attributes.

#### GROWTH COMPANIES SHOULD THINK HARD ABOUT DOING M&A


In aggregate, doing a deal isn't a good idea. The average acquirer lags its industry group by 6% over the subsequent three years following a deal (left). Clearly, performance of growth companies doing deals is much worse than value, or the middle ground, neither (right). In fact, the average growth company that does an acquisition lags its industry-group's performance by 12% over the next three years.






#### AN ALL-STOCK DEAL OF A FOREIGN PUBLIC COMPANY? NO THANKS

There is no question that the performance of companies doing all cash deals is way better than those doing all stock deals (left). The average acquirer doing an all-stock deal lags its industry group average by 11% over the next three years. Buying a foreign public company on average results in inferior performance than buying a US company (right), likely due to a realization of less cost and revenue synergies.







Source: Trivariate Research

Source: Trivariate Research

### EXPENSIVE COMPANIES SHOULDN'T BUY EXPENSIVE COMPANIES


Companies that are in the most expensive quintile of EV-to-forecasted sales and do a deal on average lag their industry group by 10% over the next three years. Valuation doesn't seem to be a differentiator for the acquirer unless the company is in the most expensive quintile (left). The target's valuation does seem to matter more. Acquisitions of targets in the cheapest quintile perform in-line with their industries over the next three years, whereas those in the most expensive quintile lag by 10% on average (right).






#### AVOID TARGETS WITH LOW MARGINS OR PROJECTED TO GROW FAST

We also analyzed the profitability and forecasted revenue growth of the companies receiving the tender offer to see if that had an impact on the subsequent stock performance of the acquirer. Performance of acquirers buying companies in the lowest net margin quintile was on average poor, lagging the acquirer's industry-average by 12% over the next three years (left). Avoiding very fast growers was also prudent (right), though this is highly correlated to the result that acquirers should avoid companies in the highest quintile of EV-to-forecasted sales.





TRIVARIATE RESEARCH

Source: Trivariate Research

#### THE MOST RECENT M&A

Below is a screen of the most recent M&A announcements. Our results are all averages for larger baskets of stocks. RDW has performed well since its announcement, but the other attributes on average result in poor 3-year relative to industry performance (growth acquirer, not a cash deal, low margin, high forecasted growth).

#### Recently Announced M&A Transaction Offerings of Public US Equities As of January 27, 2025

Announcement Date	Acquirer Ticker	Acquirer Company	Target Company	Transaction Size	Acquirer Style	Consideration Type	Net Margin Quintile	Forecast Revenue Growth Quintile
1/20/2025	RDW	Redwire Corporation	Edge Autonomy Operations	0.93	Growth	Cash & Stock	Q5	Q1
1/16/2025	SYM	Symbotic Inc.	Walmart Advanced Systems & Robotics	0.55	Growth	Cash	Q5	Q1
1/15/2025	QXO	QXO, Inc.	Beacon Roofing Supply, Inc.	11.62	Growth	Cash	Q1	
1/10/2025	CEG	Constellation Energy	Calpine Corporation	29.39	Value	Cash & Stock	Q4	Q5
1/8/2025	FLO	Flowers Foods, Inc.	Simple Mills, Inc.	0.80	Value	Cash	Q3	Q3
12/17/2024	NWBI	Northwest Bancshares	Penns Woods Bancorp, Inc.	0.27	Value	Cash & Stock	Q4	Q2
12/16/2024	BHLB	Berkshire Hills Bancorp	Brookline Bancorp, Inc.	1.14	Neither	Stock	Q5	Q2
12/13/2024	VIAV	Viavi Solutions Inc.	Inertial Labs, Inc.	0.33	Neither	Cash	Q4	Q4
12/12/2024	UPBD	Upbound Group, Inc.	Bridge IT, Inc.	0.46	Neither	Cash & Stock	Q3	Q2
12/9/2024	INDB	Independent Bank Corp.	Enterprise Bancorp, Inc.	0.56	Value	Cash & Stock	Q2	
12/9/2024	AJG	Arthur J. Gallagher & Co	. AssuredPartners, Inc.	13.45	Growth	Cash	Q3	Q2
12/9/2024	OMC	Omnicom Group Inc.	The Interpublic Group of Companies	18.20	Neither	Stock	Q1	Q3
11/25/2024	ONB	Old National Bancorp	Bremer Financial Corporation	1.40	Value	Cash & Stock	Q2	Q3
11/24/2024	OKE	ONEOK, Inc.	EnLink Midstream, LLC	10.09	Neither	Stock	Q3	Q1
11/19/2024	AMCR	Amcor plc	Berry Global Group, Inc.	18.04	Value	Stock	Q3	Q4
11/11/2024	CAH	Cardinal Health, Inc.	The GI Alliance Management	2.80	Neither	Cash	Q3	Q5
11/8/2024	ASTH	Astrana Health, Inc.	Prospect Medical Systems	0.75	Growth	Cash	Q2	Q1

#### **DISCLOSURES**

#### Disclaimer

This presentation is confidential and may not be reproduced or distributed without the express prior written permission of Trivariate Research LP and its affiliates (collectively, "Trivariate").

The information contained herein reflects the opinions and projections of Trivariate as the date of publication, which are subject to change without notice at any time subsequent to the date of issue. Trivariate does not represent that any opinion or projection expressed herein will be realized. All information provided is for informational and research purposes only and should not be deemed as investment advice or a recommendation to purchase or sell any specific portfolio investment, security or other asset. While the information presented herein is believed to be reliable, no representation or warranty is made concerning the accuracy of any data or other information presented. Information obtained by Trivariate from third party sources in connection with the preparation of this presentation has not been independently verified by Trivariate. Additional information regarding Trivariate is available on request.

Any projections, forecasts, targets or other estimates presented herein constitute "forward-looking statements" that can be identified by the use of forward-looking terminology such as "may," "will," "should," "could," "would," "predicts," "potential," "forecasted," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," or the negatives thereof or other variations thereon or comparable terminology. Furthermore, any projections, targets, forecasts or other estimates in this presentation are "forward-looking statements" and are based upon certain assumptions that may change. Due to various risks and uncertainties, actual events or results or the actual performance of the funds may differ materially from those reflected or contemplated in such forward-looking statements. Moreover, actual events are difficult to predict and often depend upon factors that are beyond the control of the Trivariate. Nothing herein is correct as of any time after the earlier of the relevant date specified herein or the date of this presentation. In addition, unless the context otherwise requires, the words "includes," "includes," "including" and other words of similar import are meant to be illustrative rather than restrictive. Forward-looking statements and discussions of the business environment included herein (e.g., With respect to financial markets, business opportunities, demand, investment pipeline and other conditions) are subject to the ongoing novel coronavirus outbreak ("COVID" or "COVID-19"). The full impact of COVID-19 is particularly uncertain and difficult to predict, therefore such forward-looking statements do not reflect its ultimate potential.

This shall not constitute an offer to sell or the solicitation of an offer to buy any interests in any fund, product or account that is or may in the future be advised or managed by, Trivariate or any of its affiliates.

All data sourced from S&P Global, Bloomberg, or our Trivariate estimates. All forward-looking-statements reflect the opinion of Trivariate.

